Robert Giffin, MD
Family Medicine · Vicksburg, MSNPI 1376584052
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$835
- AstraZeneca$460
- Astellas Pharma US Inc$337
- Amgen$228
- Bayer$212
- AbbVie$211
- plus $2K from 23 others
Across 5 payments — averaging $22,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$113K
What the payments were for
- Food & beverage$3,804100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $835 |
| AstraZeneca | 30 | $460 |
| Astellas Pharma US Inc | 9 | $337 |
| Amgen(2 entities) | 16 | $228 |
| Bayer | 10 | $212 |
| AbbVie(2 entities) | 9 | $211 |
| Abbott | 7 | $175 |
| Boehringer Ingelheim | 8 | $139 |
| Johnson & Johnson | 4 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $138 |
| Phathom Pharmaceuticals, Inc. | 4 | $129 |
| GSK | 9 | $125 |
| Idorsia Pharmaceuticals US Inc | 8 | $119 |
| Lilly USA, LLC | 6 | $85 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Pfizer | 3 | $49 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Merck | 3 | $44 |
| Stryker | 1 | $42 |
| Eisai Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Exact Sciences | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,818 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 106 | $79,634 |
| OzempicSemaglutide | 67 | $70,699 |
| EliquisApixaban | 97 | $57,566 |
| TrulicityDulaglutide | 38 | $47,265 |
| FarxigaDapagliflozin Propanediol | 81 | $45,225 |
| RybelsusSemaglutide | 30 | $40,843 |
| JanuviaSitagliptin Phosphate | 44 | $39,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $31,322 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $19,198 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $16,024 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $11,805 |
| MyrbetriqMirabegron | 17 | $7,092 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $6,234 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,042 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $4,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $835 | $111,54297 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $139 | $91,440121 claims |
| PfizerEliquis, Premarin | $49 | $61,567108 claims |
| MerckJanuvia, Janumet | $44 | $59,13165 claims |
| Lilly USA, LLCTrulicity | $85 | $47,26538 claims |
| AstraZenecaFarxiga | $460 | $45,22581 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $125 | $35,40360 claims |
| Astellas Pharma US IncMyrbetriq | $337 | $7,09217 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $3,35312 claims |
| AbbVieSynthroid | $211 | $2,18628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Vicksburg
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Delora DenneyPicayune$24K
- Randall HulingOlive Branch$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.